Open AccessHuman Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy
Author(s) -
Timothy J. Henrich,
Kristen S. Hobbs,
Emily Hanhauser,
Eileen P. Scully,
Louise E. Hogan,
Yvonne Robles,
Kaitlyn S. Leadabrand,
Francisco M. Marty,
Christine D. Palmer,
Stéphanie Jost,
Christian Körner,
Jonathan Z. Li,
Rajesh T. Gandhi,
Ayad Hamdan,
Jeremy S. Abramson,
Ann S. LaCasce,
Daniel R. Kuritzkes
Publication year - 2017
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jix265
Subject(s) - immunology , virology , immune system , biology , population , chemotherapy , virus , viral load , t cell , immunodeficiency , medicine , genetics , environmental health
Systemic chemotherapies for various malignancies have been shown to significantly, yet transiently, decrease numbers of CD4+ T lymphocytes, a major reservoir for human immunodeficiency virus type 1 (HIV-1) infection. However, little is known about the impact of cytoreductive chemotherapy on HIV-1 reservoir dynamics, persistence, and immune responses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom